Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Federal Trade Commission
Cantor Fitzgerald
Cerilliant
Deloitte
Medtronic
Boehringer Ingelheim
Teva
Johnson and Johnson

Generated: June 22, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 018487

« Back to Dashboard

NDA 018487 describes FUROSEMIDE, which is a drug marketed by Abraxis Pharm, Accord Hlthcare, Amneal Pharms Co, Astrazeneca, Baxter Hlthcare Corp, Emcure Pharms Ltd, Fresenius Kabi Usa, Hospira, Igi Labs Inc, Intl Medication, Luitpold, Marsam Pharms Llc, Smith And Nephew, Warner Chilcott, Watson Labs, West-ward Pharms Int, Wockhardt, Wyeth Ayerst, Wockhardt Bio Ag, Dava Pharms Inc, Ipca Labs Ltd, Ivax Sub Teva Pharms, Kalapharm, Leading Pharma Llc, Mylan, Prinston Inc, Sandoz, Sun Pharm Inds Inc, Sun Pharm Industries, Superpharm, and Watson Labs Teva, and is included in fifty-seven NDAs. It is available from sixty-two suppliers. Additional details are available on the FUROSEMIDE profile page.

The generic ingredient in FUROSEMIDE is furosemide. There are twenty-one drug master file entries for this compound. Sixty-four suppliers are listed for this compound. Additional details are available on the furosemide profile page.
Summary for 018487
Tradename:FUROSEMIDE
Applicant:Mylan
Ingredient:furosemide
Patents:0
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 018487
Medical Subject Heading (MeSH) Categories for 018487
Suppliers and Packaging for NDA: 018487
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
FUROSEMIDE furosemide TABLET;ORAL 018487 NDA Mylan Pharmaceuticals Inc. 0378-0208 N 0378-0208-01
FUROSEMIDE furosemide TABLET;ORAL 018487 NDA Mylan Pharmaceuticals Inc. 0378-0208 N 0378-0208-10

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength20MG
Approval Date:Approved Prior to Jan 1, 1982TE:ABRLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength40MG
Approval Date:Approved Prior to Jan 1, 1982TE:ABRLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Cipla
Farmers Insurance
Accenture
Johnson and Johnson
Boehringer Ingelheim
AstraZeneca
Federal Trade Commission
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.